Hamel Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.4M | Buy |
21,448
+308
| +1% | +$66.3K | 1.49% | 27 |
|
|
2026
Q1 | $4.6M | Buy |
21,140
+585
| +3% | +$130K | 1.31% | 30 |
|
|
2025
Q4 | $4.7M | Hold |
20,555
| – | – | 1.42% | 29 |
|
|
2025
Q3 | $4.76M | Hold |
20,555
| – | – | 1.46% | 29 |
|
|
2025
Q2 | $3.82M | Sell |
20,555
-150
| -0.7% | -$27.9K | 1.29% | 31 |
|
|
2025
Q1 | $4.34M | Buy |
20,705
+150
| +0.7% | +$29.2K | 1.47% | 29 |
|
|
2024
Q4 | $3.65M | Hold |
20,555
| – | – | 1.18% | 31 |
|
|
2024
Q3 | $4.06M | Hold |
20,555
| – | – | 1.24% | 32 |
|
|
2024
Q2 | $3.53M | Sell |
20,555
-3,666
| -15% | -$607K | 1.11% | 33 |
|
|
2024
Q1 | $4.41M | Sell |
24,221
-2,975
| -11% | -$513K | 1.41% | 29 |
|
|
2023
Q4 | $4.21M | Sell |
27,196
-225
| -0.8% | -$32.8K | 1.49% | 26 |
|
|
2023
Q3 | $4.09M | Hold |
27,421
| – | – | 1.49% | 28 |
|
|
2023
Q2 | $3.69M | Sell |
27,421
-225
| -0.8% | -$33K | 1.29% | 32 |
|
|
2023
Q1 | $4.41M | Sell |
27,646
-65
| -0.2% | -$9.94K | 1.53% | 27 |
|
|
2022
Q4 | $4.48M | Sell |
27,711
-250
| -0.9% | -$38.3K | 1.56% | 26 |
|
|
2022
Q3 | $3.75M | Sell |
27,961
-300
| -1% | -$43K | 1.49% | 25 |
|
|
2022
Q2 | $4.33M | Sell |
28,261
-250
| -0.9% | -$38.2K | 1.71% | 21 |
|
|
2022
Q1 | $4.62M | Sell |
28,511
-4
| -0% | -$581 | 1.64% | 23 |
|
|
2021
Q4 | $3.86M | Buy |
28,515
+50
| +0.2% | +$5.91K | 1.38% | 27 |
|
|
2021
Q3 | $3.07M | Buy |
28,465
+1,310
| +5% | +$150K | 1.2% | 35 |
|
|
2021
Q2 | $3.06M | Buy |
27,155
+13,250
| +95% | +$1.49M | 1.17% | 37 |
|
|
2021
Q1 | $1.5M | Buy |
+13,905
| New | +$1.49M | 0.58% | 48 |
|
|
2018
Q1 | – | Sell |
-2,150
| Closed | -$208K | – | 92 |
|
|
2017
Q4 | $208K | Buy |
+2,150
| New | +$203K | 0.1% | 83 |
|
|
2017
Q1 | – | Sell |
-10,075
| Closed | -$631K | – | 79 |
|
|
2016
Q4 | $631K | Sell |
10,075
-1,475
| -13% | -$90K | 0.33% | 57 |
|
|
2016
Q3 | $728K | Sell |
11,550
-10,000
| -46% | -$647K | 0.39% | 54 |
|
|
2016
Q2 | $1.33M | Sell |
21,550
-1,200
| -5% | -$73.1K | 0.69% | 46 |
|
|
2016
Q1 | $1.3M | Sell |
22,750
-250
| -1% | -$13.9K | 0.69% | 46 |
|
|
2015
Q4 | $1.36M | Sell |
23,000
-450
| -2% | -$25.9K | 0.87% | 38 |
|
|
2015
Q3 | $1.28M | Hold |
23,450
| – | – | 0.91% | 37 |
|
|
2015
Q2 | $1.58M | Buy |
23,450
+1,025
| +5% | +$66.9K | 1.04% | 36 |
|
|
2015
Q1 | $1.31M | Buy |
22,425
+1,300
| +6% | +$78.5K | 0.87% | 43 |
|
|
2014
Q4 | $1.38M | Hold |
21,125
| – | – | 0.9% | 43 |
|
|
2014
Q3 | $1.22M | Sell |
21,125
-2,225
| -10% | -$124K | 0.81% | 45 |
|
|
2014
Q2 | $1.32M | Sell |
23,350
-100
| -0.4% | -$5.25K | 0.87% | 39 |
|
|
2014
Q1 | $1.21M | Sell |
23,450
-5,225
| -18% | -$264K | 0.83% | 45 |
|
|
2013
Q4 | $1.51M | Buy |
+28,675
| New | +$1.41M | 1.06% | 35 |
|
Other funds holding ABBV
ECSS
ATO
Hamel Associates's ABBV Position: Q2 2026 in Review
Hamel Associates increased its AbbVie (ABBV) stake by 1.5% in Q2 2026, buying an estimated $66.3K and bringing the position to 21,448 shares worth $5.4M. The position accounts for 1.49% of the portfolio, ranked #27.
Hamel Associates first reported a position in ABBV in Q4 2013 and has held it in 36 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Hamel Associates held 21,448 shares of AbbVie worth $5.4M as of Q2 2026.
- Hamel Associates bought 308 AbbVie shares in Q2 2026, an estimated $66.3K.
- AbbVie made up 1.49% of Hamel Associates's portfolio in Q2 2026, its #27 holding.
- Hamel Associates first reported a position in AbbVie in Q4 2013 and has held it in 36 quarters since.
- 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Hamel Associates's 13F filing for Q2 2026, filed 27 Jul 2026.